Adaptimmune’s GSK-partnered T cells trigger responses in solid tumor patients

Adaptimmune has seen partial responses in three of the first four myxoid/round cell liposarcoma (MRCLS) patients treated with its T cells. The early data raised hopes the GlaxoSmithKline-partnered drug will be effective in multiple types of solid tumor, sending Adaptimmune shares up nearly 20%.

• Source: Fiercebiotech
• 568
• March 20, 2018